Results vary based on lifestyle and adherence to treatment
In a study involving a maternal immune activation (MIA) model, adult male mice with autism-like features were treated with Melanotan 2 over seven days
[1] Important safety considerations include the risk of hypoglycaemia when combined with insulin or sulfonylureas, potential dehydration and acute kidney injury with severe gastrointestinal symptoms, and for semaglutide specifically, possible worsening of diabetic retinopathy in those with pre-existing disease
Small deviations appear well-tolerated
But if you chug so much caffeine the neighborhood barista knows your name (and can spell it right on the cup), youre trying to fix a bullet hole with a Band-Aid, bub
Summary: There is no universal medical requirement to gradually wean off GLP-1 receptor agonists, as they do not typically cause physical dependence or withdrawal symptoms requiring dose tapering